SV2008002612A - Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo - Google Patents
Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvoInfo
- Publication number
- SV2008002612A SV2008002612A SV2006002612A SV2006002612A SV2008002612A SV 2008002612 A SV2008002612 A SV 2008002612A SV 2006002612 A SV2006002612 A SV 2006002612A SV 2006002612 A SV2006002612 A SV 2006002612A SV 2008002612 A SV2008002612 A SV 2008002612A
- Authority
- SV
- El Salvador
- Prior art keywords
- oral
- approximately
- delayed
- dosage form
- hours
- Prior art date
Links
- 230000003111 delayed effect Effects 0.000 title abstract 4
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69962305P | 2005-07-15 | 2005-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2008002612A true SV2008002612A (es) | 2008-08-29 |
Family
ID=37669348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2006002612A SV2008002612A (es) | 2005-07-15 | 2006-07-13 | Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070014859A1 (enExample) |
| EP (1) | EP1904040A2 (enExample) |
| JP (1) | JP2009501233A (enExample) |
| KR (1) | KR20080025405A (enExample) |
| CN (1) | CN101247791A (enExample) |
| AR (1) | AR054833A1 (enExample) |
| AU (1) | AU2006270315A1 (enExample) |
| BR (1) | BRPI0613484A2 (enExample) |
| CA (1) | CA2612960A1 (enExample) |
| CR (1) | CR9626A (enExample) |
| EC (1) | ECSP088106A (enExample) |
| GT (1) | GT200600307A (enExample) |
| IL (1) | IL188313A0 (enExample) |
| MX (1) | MX2008000666A (enExample) |
| NO (1) | NO20080088L (enExample) |
| PE (1) | PE20070192A1 (enExample) |
| RU (1) | RU2007148195A (enExample) |
| SV (1) | SV2008002612A (enExample) |
| TW (1) | TW200740427A (enExample) |
| WO (1) | WO2007011619A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200706804B (en) | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| ES2335919T3 (es) * | 2005-03-31 | 2010-04-06 | Wyeth | Producto de combinacion de o-desmetilvenlafaxina y bazedosifeno, y sus usos. |
| US20080175873A1 (en) * | 2005-06-02 | 2008-07-24 | Biovail Laboratories International S.R.L. | Modified release composition of at least one form of venlafaxine |
| CA2626326C (en) | 2005-11-04 | 2021-02-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| JP2009518407A (ja) * | 2005-12-05 | 2009-05-07 | ワイス | 置換１−（２−アミノ−１−フェニル−エチル）−シクロヘキサノールのエナンチオマーを選択的に合成するための方法 |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| BRPI0812501A2 (pt) * | 2007-07-12 | 2015-06-16 | Reddys Lab Ltd Dr | O-desmetil venlafaxina |
| CA2702664A1 (en) * | 2007-10-16 | 2009-04-23 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US20110027324A1 (en) * | 2007-12-10 | 2011-02-03 | Wyeth Llc | O-desmethyl-venlafaxine for treating major depressive disorder |
| DK2310011T3 (da) | 2008-06-17 | 2013-10-14 | Wyeth Llc | Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin |
| CA2730715C (en) | 2008-08-04 | 2013-10-01 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| CN101716168B (zh) * | 2008-10-09 | 2014-09-17 | 北京德众万全医药科技有限公司 | 一种含有去甲文拉法新的盐的药物组合物及其制备方法 |
| EP2191822A1 (en) * | 2008-11-26 | 2010-06-02 | LEK Pharmaceuticals d.d. | Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine |
| KR20140036332A (ko) | 2009-04-06 | 2014-03-25 | 와이어쓰 엘엘씨 | 네라티닙을 이용한 유방암의 치료법 |
| CN102724962B (zh) * | 2009-11-09 | 2017-05-17 | 惠氏有限责任公司 | 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 |
| BR112012024576A2 (pt) * | 2010-03-31 | 2016-05-31 | Wockhardt Ltd | composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição |
| CN102085197B (zh) * | 2010-12-14 | 2013-08-14 | 北京万生药业有限责任公司 | 一种文拉法辛缓释制剂及其制备方法 |
| WO2012140577A1 (en) | 2011-04-12 | 2012-10-18 | Lupin Limited | Modified release pharmaceutical compositions of desvenlafaxine |
| CN111008356B (zh) * | 2019-11-13 | 2023-06-16 | 成都理工大学 | 一种基于WTSVD算法扣除背景的γ能谱集分析方法 |
| CN114288273B (zh) * | 2022-02-11 | 2022-10-18 | 桂林华信制药有限公司 | 一种盐酸文拉法辛缓释胶囊及其生产工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| WO2000076955A1 (en) * | 1999-06-15 | 2000-12-21 | American Home Products Corporation | Enantiomers of o-desmethyl venlafaxine |
| AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
| AU2003226752A1 (en) * | 2002-03-28 | 2003-10-13 | Synthon B.V. | Venlafaxine base |
| US6703044B1 (en) * | 2002-10-25 | 2004-03-09 | Dexcel Pharma Tech, Ltd | Venlafaxine formulations |
| ES2277030T3 (es) * | 2003-05-02 | 2007-07-01 | Dexcel Ltd. | Formulacion en comprimidos de venlafaxina de liberacion prolongada. |
| EP1711167A1 (en) * | 2004-02-06 | 2006-10-18 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
-
2006
- 2006-07-13 PE PE2006000833A patent/PE20070192A1/es not_active Application Discontinuation
- 2006-07-13 GT GT200600307A patent/GT200600307A/es unknown
- 2006-07-13 MX MX2008000666A patent/MX2008000666A/es not_active Application Discontinuation
- 2006-07-13 AU AU2006270315A patent/AU2006270315A1/en not_active Abandoned
- 2006-07-13 US US11/486,324 patent/US20070014859A1/en not_active Abandoned
- 2006-07-13 BR BRPI0613484A patent/BRPI0613484A2/pt not_active IP Right Cessation
- 2006-07-13 CN CNA2006800258002A patent/CN101247791A/zh active Pending
- 2006-07-13 EP EP06787061A patent/EP1904040A2/en not_active Withdrawn
- 2006-07-13 AR ARP060103012A patent/AR054833A1/es unknown
- 2006-07-13 CA CA002612960A patent/CA2612960A1/en not_active Abandoned
- 2006-07-13 SV SV2006002612A patent/SV2008002612A/es unknown
- 2006-07-13 TW TW095125660A patent/TW200740427A/zh unknown
- 2006-07-13 RU RU2007148195/15A patent/RU2007148195A/ru unknown
- 2006-07-13 WO PCT/US2006/027106 patent/WO2007011619A2/en not_active Ceased
- 2006-07-13 JP JP2008521581A patent/JP2009501233A/ja not_active Withdrawn
- 2006-07-13 KR KR1020087001067A patent/KR20080025405A/ko not_active Withdrawn
-
2007
- 2007-12-20 IL IL188313A patent/IL188313A0/en unknown
- 2007-12-20 CR CR9626A patent/CR9626A/es not_active Application Discontinuation
-
2008
- 2008-01-07 NO NO20080088A patent/NO20080088L/no not_active Application Discontinuation
- 2008-01-14 EC EC2008008106A patent/ECSP088106A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20070192A1 (es) | 2007-03-16 |
| MX2008000666A (es) | 2008-03-13 |
| TW200740427A (en) | 2007-11-01 |
| AU2006270315A1 (en) | 2007-01-25 |
| NO20080088L (no) | 2008-04-02 |
| CN101247791A (zh) | 2008-08-20 |
| AR054833A1 (es) | 2007-07-18 |
| WO2007011619A2 (en) | 2007-01-25 |
| US20070014859A1 (en) | 2007-01-18 |
| GT200600307A (es) | 2008-04-24 |
| EP1904040A2 (en) | 2008-04-02 |
| ECSP088106A (es) | 2008-02-20 |
| CA2612960A1 (en) | 2007-01-25 |
| IL188313A0 (en) | 2008-04-13 |
| KR20080025405A (ko) | 2008-03-20 |
| CR9626A (es) | 2008-04-10 |
| RU2007148195A (ru) | 2009-08-20 |
| JP2009501233A (ja) | 2009-01-15 |
| BRPI0613484A2 (pt) | 2016-11-16 |
| WO2007011619A3 (en) | 2007-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2008002612A (es) | Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo | |
| HRP20060147B1 (hr) | Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu | |
| BRPI0515316A (pt) | compostos de imidazoquinolina | |
| AU2003274681A1 (en) | Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release | |
| BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
| RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| CR10732A (es) | Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina | |
| CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
| TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
| UY31403A1 (es) | "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos". | |
| TW200640497A (en) | Pharmaceutical formulations and methods of use | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
| PE20080400A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
| EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| PA8586301A1 (es) | Formulaciones de liberacion prolongada en forma de suspension | |
| UA87841C2 (ru) | Композиция, которая содержит амброксол, для местного применения | |
| MX2007000117A (es) | Una composicion de combinacion. | |
| WO2004022002A3 (en) | Combined immediate release and extended release analgesic composition | |
| PE20081072A1 (es) | Composiciones de anti-histaminicos, descongestivos, antitusivos y drogas anti-inflamatorios no esteroidales | |
| TW200509863A (en) | Irradiation device for medical use | |
| BRPI0508680A (pt) | composição de resfriamento natural, composição flavorizante, produto pronto-para-consumo, e, uso de uma composição | |
| EA200700055A1 (ru) | Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением | |
| BR0306923A (pt) | Composição farmacêutica para regeneração de tecidos hepáticos para tratamento de cirrose do fìgado uso de 5-(2-pirazinil) -4-metil-1,2-ditiol-3-tiona | |
| AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. |